600557.SHG Jiangsu Kanion Pharmaceutical Co Ltd
- Market cap
- CNY 7.26B
- P/E
- 22.9x
- P/B
- 1.44x
- ROE
- 5.7%
- Dividend yield
- 1.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600557.SHG undervalued?
Graham number600557.SHG trades 21.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Kanion Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Kanion Pharmaceutical Co Ltd yet.
Jiangsu Kanion Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals. The company offers Chinese medicine for anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. It also provides herb extracts and formula granules, well as OEM/ODM services. The company was founded in 1975 and is based in Lianyungang, China.
Full company profileJiangsu Kanion Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Kanion Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.00B | 3.27B | 3.82B | 4.57B | 3.03B | 3.65B | 4.35B | 4.86B | 3.90B | 3.29B | 3.23B |
| Gross Profit | 2.24B | 2.48B | 2.92B | 3.56B | 2.21B | 2.63B | 3.14B | 3.61B | 2.83B | 2.35B | 2.30B |
| Operating Income | 387M | 442M | 483M | 579M | 351M | 351M | 455M | 461M | 385M | 375M | 327M |
| EBITDA | 612M | 641M | 690M | 781M | 478M | 527M | 638M | 644M | 604M | 562M | 357M |
| Net Income | 374M | 374M | 414M | 507M | 263M | 321M | 434M | 464M | 392M | 304M | 282M |
| EPS | 0.61 | 0.63 | 0.70 | 0.86 | 0.44 | 0.56 | 0.75 | 0.80 | 0.68 | 0.54 | 0.50 |
| Balance Sheet | |||||||||||
| Total Assets | 4.73B | 5.39B | 5.60B | 6.11B | 6.12B | 6.02B | 6.80B | 7.12B | 6.91B | 6.86B | 6.95B |
| Total Liabilities | 1.52B | 1.80B | 1.71B | 2.02B | 1.79B | 1.55B | 1.86B | 1.74B | 2.20B | 1.85B | 1.77B |
| Shareholders' Equity | 3.14B | 3.49B | 3.89B | 3.94B | 4.17B | 4.30B | 4.75B | 5.19B | 4.51B | 4.82B | 4.98B |
| Cash & Short-term Investments | 248M | 295M | 378M | 409M | 773M | 1.11B | 1.77B | 2.43B | 2.24B | 2.15B | 2.04B |
| Total Debt | 275M | 680M | 635M | 685M | 488M | 235M | 11.9M | 1.93M | 548M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 299M | 383M | 636M | 926M | 701M | 908M | 996M | 972M | 702M | 611M | - |
| Capital Expenditure | 325M | 261M | 316M | 490M | 190M | 172M | 211M | 297M | 477M | 522M | 556M |
| Free Cash Flow | -26.2M | 122M | 321M | 436M | 511M | 737M | 785M | 744M | 226M | 88.8M | -111M |
| Ratios | |||||||||||
| ROE | 11.9% | 10.7% | 10.6% | 12.9% | 6.3% | 7.4% | 9.1% | 8.9% | 8.7% | 6.3% | 5.7% |
| ROA | 7.9% | 6.9% | 7.4% | 8.3% | 4.3% | 5.3% | 6.4% | 6.5% | 5.7% | 4.4% | 4.1% |
| Net Profit Margin | 12.5% | 11.4% | 10.8% | 11.1% | 8.7% | 8.8% | 10.0% | 9.5% | 10.1% | 9.2% | 8.7% |
| Debt to Equity | 0.09x | 0.20x | 0.16x | 0.17x | 0.12x | 0.05x | 0.00x | 0.00x | 0.12x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Kanion Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.27%
- Forward dividend
- -
- Payout ratio
- 30.2%
- Ex-dividend date
- May 31, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 91.9M | 0.16 | 30.2% |
| 2024 | CNY 214M | 0.37 | 54.5% |
| 2023 | CNY 129M | 0.22 | 27.7% |
| 2022 | CNY 2.49M | 0.00 | 0.6% |
| 2021 | CNY 11.1M | 0.02 | 3.4% |
| 2020 | CNY 47.4M | 0.08 | 18.0% |
| 2019 | CNY 47.4M | 0.08 | 9.4% |
| 2018 | CNY 37.0M | 0.06 | 8.9% |
| 2017 | CNY 90.1M | 0.15 | 24.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12:10 on Jun 24, 2016.
Who owns Jiangsu Kanion Pharmaceutical Co Ltd
- Insiders 43.38%
- Institutions 4.17%
- Public & others 52.45%
- Shares outstanding 566M
- Free float 344M
Jiangsu Kanion Pharmaceutical Co Ltd company profile
- Company name
- Jiangsu Kanion Pharmaceutical Co Ltd
- Ticker
- 600557.SHG
- ISIN
- CNE000001CL7
- Exchange
- Shanghai Stock Exchange
- Listed since
- Sep 18, 2002
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,379
- Fiscal year end
- December
- Address
- Economic and development zone, Lianyungang, China, 222000
- Phone
- 86 51 8855 21990
- Website
- kanion.com
About Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals. The company offers Chinese medicine for anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. It also provides herb extracts and formula granules, well as OEM/ODM services. The company was founded in 1975 and is based in Lianyungang, China.
Jiangsu Kanion Pharmaceutical Co Ltd management
8- Mr. Yongchun YangGM & Director · born 1973
- Mr. Li QingCFO & Accounting Supervisor · born 1990
- Mr. Pan PengSecretary · born 1976
- Mr. Quan LiuDeputy General Manager · born 1979
- Mr. Yu PanDeputy GM & Market Development Center · born 1971
- Mr. Chuanlei WangDeputy General Manager · born 1975
- Mr. Jie Wang TuanDeputy General Manager · born 1986
- Xiaoliang ZhangDeputy General Manager